×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
Mutual Fund Summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Ads
Alembic Pharma Q2 PAT may dip 49.2% YoY to Rs 169.4 cr: ICICI Direct
Alembic Pharmaceuticals Q1 PAT may dip 28.7% YoY to Rs 215 cr: KRChoksey
Alembic Pharma Q1 PAT may dip 20.3% YoY to Rs 240.2 cr: ICICI Direct
Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct
India Inc’s profits to suffer hard knock from inventory losses – Part I
Alembic Pharma reports better numbers in Q3; here are highlights of analyst call
'Q2 review: Bet on these 13 stocks for strong growth in FY21'
Alembic Pharma Q3 PAT seen up 7.7% YoY to Rs. 140.6 cr: ICICI Direct
Alembic Pharma Q2 PAT may dip 9.3% YoY to Rs. 110 cr: HDFC Securities
Alembic Pharma Q2 PAT may dip 4.5% YoY to Rs. 116.1 cr: ICICI Direct
Alembic Pharma Q4 PAT seen up 55.6% YoY to Rs. 148.3 cr: KR Choksey
Alembic Pharma Q4 PAT seen up 0.3% YoY to Rs. 90 cr: HDFC Securities
Alembic Pharma Q1 PAT may dip 16.70% YoY to Rs 86.3 cr: KR Choksey
Alembic Pharma Q4 PAT seen up 7.4% to Rs 92.9 cr: ICICI Securities
Alembic Pharma Q3 profit seen down 60%, margin may shrink 20%
Alembic Pharma Q3 PAT may dip 16% to Rs 100 cr: HDFC Securities
Alembic Pharma Q3 PAT may dip 22% to Rs 94 cr: ICICI Securities
Alembic Pharma Q3 PAT may dip 27.1% to Rs 87.3 cr: KR Choksey
We are planning 6-8 new launches this fiscal yr: Alembic Pharma
EBITDA margin came off unusually high base: Alembic Pharma
Alembic Pharma expects API biz to grow 10% in FY15
See 20% EBITDA growth in FY14: Alembic Pharma
See 100-120 bps margin improvement in FY14: Alembic Pharma
See pharma sector's margins to dip 314 bps in 3QFY13: Angel
ANDAs will benefit FY13 and FY14 numbers: Alembic Pharma
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio